Castration-resistant Prostate Cancer Clinical Trials in Shanghai, Shanghai Municipality
9 recruitingShanghai, Shanghai Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 1Phase 2
A Study of MHB048C in Patients With Advanced Solid Tumors
Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
Metastatic Castration-Resistant Prostate Cancer Patients
Tasly Pharmaceutical Group Co., Ltd78 enrolled1 locationNCT07514065
Recruiting
Phase 3
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.370 enrolled1 locationNCT07311694
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.84 enrolled27 locationsNCT06155084
Recruiting
Phase 2
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
Metastatic Castration-resistant Prostate Cancer (mCRPC)
MediLink Therapeutics (Suzhou) Co., Ltd.100 enrolled24 locationsNCT06241846
Recruiting
Phase 1
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Metastatic Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer
Shanghai Changzheng Hospital3 enrolled1 locationNCT06895811
Recruiting
Early Phase 1
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC
Metastatic Castration-resistant Prostate CancerCastration-resistant Prostate Cancer
Shanghai Changzheng Hospital18 enrolled1 locationNCT06228404